Patents by Inventor Christopher Michael Tegley

Christopher Michael Tegley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11970481
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
    Type: Grant
    Filed: October 4, 2023
    Date of Patent: April 30, 2024
    Assignee: NURA BIO, INC.
    Inventors: Jennifer Aiden Kozak, Sean Pomeroy Brown, Christopher Michael Tegley, Alexander Wayne Schammel, Liusheng Zhu, Maximiliano De La Higuera Macias, Shilpa Sambashivan
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20240116901
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing a neurological diseases.
    Type: Application
    Filed: October 4, 2023
    Publication date: April 11, 2024
    Inventors: Jennifer Aiden KOZAK, Sean Pomeroy BROWN, Christopher Michael TEGLEY, Alexander Wayne SCHAMMEL, Liusheng ZHU, Maximiliano DE LA HIGUERA MACIAS, Shilpa SAMBASHIVAN
  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11945796
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological diseases.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: April 2, 2024
    Assignee: NURA BIO, INC.
    Inventors: Sean Pomeroy Brown, Keira Garland, Shilpa Sambashivan, Christopher Michael Tegley, Liusheng Zhu
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20230286941
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Application
    Filed: March 3, 2023
    Publication date: September 14, 2023
    Inventors: Rao KOLLURI, Christopher Michael TEGLEY, Liusheng ZHU, Sean Pomeroy BROWN, Charles Howard REYNOLDS, Andrew Stewart TASKER, Cheryl A. GRICE
  • Substituted pyridine derivatives as SARM1 inhibitors
    Patent number: 11629136
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: April 18, 2023
    Assignee: NURA BIO, INC.
    Inventors: Rao Kolluri, Christopher Michael Tegley, Liusheng Zhu, Sean Pomeroy Brown, Charles Howard Reynolds, Andrew Stewart Tasker, Cheryl A. Grice
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20230105696
    Abstract: This disclosure is drawn to pyridine derivatives, compositions thereof, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological disorders.
    Type: Application
    Filed: July 27, 2022
    Publication date: April 6, 2023
    Inventors: Rao KOLLURI, Christopher Michael TEGLEY, Liusheng ZHU, Sean Pomeroy BROWN, Charles Howard REYNOLDS, Andrew Stewart TASKER, Cheryl A. GRICE
  • SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS
    Publication number: 20220081417
    Abstract: This disclosure is drawn to substituted pyridine compounds and compositions, and associated methods, useful for inhibition of SARM1 activity and/or for treating or preventing neurological diseases.
    Type: Application
    Filed: September 15, 2021
    Publication date: March 17, 2022
    Inventors: Sean Pomeroy Brown, Keira Garland, Shilpa Sambashivan, Christopher Michael Tegley, Liusheng Zhu
  • Compounds that interact with glucokinase regulatory protein for the treatment of diabetes
    Patent number: 8431563
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: April 30, 2013
    Assignee: Amgen Inc.
    Inventors: Kate Ashton, Michael David Bartberger, Yunxin Bo, Marian C. Bryan, Michael Croghan, Christopher Harold Fotsch, Clarence Henderson Hale, Roxanne Kay Kunz, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Lewis Dale Pennington, Steve Fong Poon, Markian Myroslaw Stec, David Joseph St. Jean, Jr., Nuria A. Tamayo, Christopher Michael Tegley, Kevin Chao Yang
  • COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES
    Publication number: 20120225854
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts thereof, that interact with glucokinase regulatory protein. In addition, the present invention relates to methods of treating type 2 diabetes, and other diseases and/or conditions where glucokinase regulatory protein is involved using the compounds, or pharmaceutically acceptable salts thereof, and pharmaceutical compositions that contain the compounds, or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: August 23, 2011
    Publication date: September 6, 2012
    Applicant: AMGEN INC.
    Inventors: Kate Ashton, Michael David Bartberger, Yunxin Bo, Marian C. Bryan, Michael Croghan, Christopher Harold Fotsch, Clarence Henderson Hale, Roxanne Kay Kunz, Longbin Liu, Nobuko Nishimura, Mark H. Norman, Lewis Dale Pennington, Steve Fong Poon, Markian Myroslaw Stec, David Joseph St. Jean, JR., Nuria A. Tamayo, Christopher Michael Tegley, Kevin Chao Yang